NCT06644534Phase 2Completed

A Study to Assess TTI-0102 vs Placebo in MELAS Patients

Study sponsor: Thiogenesis Therapeutics, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-01-12Actual

Enrollment · participants9Actual

Source updated2026-07-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-24 · 5 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~12 participants (planned)~~

+ After

9 participants (actual)

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~30 Apr 2026~~

+ After

12 Jan 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Completed

Check registry source

Study details

Conditions studied

MELAS Syndrome; Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)

Treatments or interventions studied

TTI-0102Drug
PlaceboDrug

Primary outcomes · main study measures

measure: Efficacy: Change in functional capacity; description: 12-minute walking test (12-MWT); timeFrame: Day 1/Baseline to Week 24/Study Exit; measure: Safety and Tolerability: Incidence of Treatment-Emergent Adverse Events; description: Adverse Events; timeFrame: Day 1/Baseline to Week 24/Study Exit

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history